-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Genxi Biotechnology Group announced that Dr.
Jenny Ni has been appointed as the company's Chief Technology Officer (CTO), who is fully responsible for CAR-T product development, production process and control, and supply chain management
.
The addition of Dr.
Dr.
Ni has more than 25 years of industry experience, has served many multinational pharmaceutical companies and biotechnology companies, and has deep experience accumulation in the field of gene and cell therapy and vaccine technology and product development
.
Before joining Genxi Bio, Dr.
"We very much welcome Dr.
Ni to join Genxi as the chief technology officer," said Dr.
Wei Cao (William Cao), founder, chairman and CEO of Genxi.
"Production and preparation are carried out throughout the clinical development of CAR-T cell therapy.
The key element to the commercialization stage
.
Genxi Biology's independent production base in Suzhou and the process development center in Shanghai have established a strong supply guarantee for the company's continuous expansion of product pipelines
"Genxi Bio has successfully established an independent production base and R&D center that meets GMP standards in China, and through cooperation with Lonza Group, it has begun to build a cGMP process with international leading standards in the United States
.
The comprehensive production capacity layout strategy is The company has laid a solid foundation for various pre-clinical and clinical studies
